Patents by Inventor Amy M. Nguyen

Amy M. Nguyen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for killing HIV-infected cells using Bcl-2 inhibitors
    Patent number: 11938098
    Abstract: This document provides methods and materials involved in killing HIV infected cells (e.g., CD4 T cells). For example, methods and materials for using one or more Bcl-2 inhibitors (e.g., ABT-199) alone or in combination with one or more agents capable of reactivating HIV (e.g., latency reversing agent) to kill HIV infected cells (e.g., CD4 T cells) are provided.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: March 26, 2024
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Andrew D. Badley, Amy M. Nguyen, Scott H. Kaufmann, Yuan-Ping Pang, Haiming Dai
  • METHODS AND MATERIALS FOR KILLING HIV INFECTED CELLS
    Publication number: 20210379086
    Abstract: This document provides methods and materials involved in killing HIV infected cells (e.g., CD4 T cells). For example, methods and materials for using one or more Bcl-2 inhibitors (e.g., ABT-199) alone or in combination with one or more agents capable of reactivating HIV (e.g., latency reversing agent) to kill HIV infected cells (e.g., CD4 T cells) are provided.
    Type: Application
    Filed: March 16, 2021
    Publication date: December 9, 2021
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Andrew D. Badley, Amy M. Nguyen, Scott H. Kaufmann, Yuan-Ping Pang, Haiming Dai
  • METHODS AND MATERIALS FOR KILLING HIV INFECTED CELLS
    Publication number: 20180161347
    Abstract: This document provides methods and materials involved in killing HIV infected cells (e.g., CD4 T cells). For example, methods and materials for using one or more Bcl-2 inhibitors (e.g., ABT-199) alone or in combination with one or more agents capable of reactivating HIV (e.g., latency reversing agent) to kill HIV infected cells (e.g., CD4 T cells) are provided.
    Type: Application
    Filed: April 20, 2016
    Publication date: June 14, 2018
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Andrew D. Badley, Amy M. Nguyen, Scott H. Kaufmann, Yuan-Ping Pang, Haiming Dai